News >

Future of mCRC Lies in Biomarker-Directed Therapies

Kristi Rosa
Published: Wednesday, Jun 12, 2019

Christopher Lieu, MD

Christopher Lieu, MD

Some of the most exciting research being conducted in metastatic colorectal cancer (mCRC) has been in the form of biomarker-directed therapy and immunotherapy, said Christopher Lieu, MD. Although these advances have been made in only a small percentage of the overall population, these personalized approaches have led to significant improvements in survival.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x